Santen Pharmaceutical Co., Ltd. (SNPHY)
12.67
+0.14
(+1.12%)
USD |
OTCM |
Nov 13, 16:00
Santen Pharmaceutical Enterprise Value : 3.756B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 3.756B |
| November 12, 2026 | 3.711B |
| November 11, 2026 | 3.756B |
| November 10, 2026 | 3.756B |
| November 09, 2026 | 3.756B |
| November 06, 2026 | 3.524B |
| November 05, 2026 | 3.753B |
| November 04, 2026 | 3.366B |
| November 03, 2026 | 3.327B |
| November 02, 2026 | 3.371B |
| October 30, 2026 | 3.294B |
| October 29, 2026 | 3.148B |
| October 28, 2026 | 3.222B |
| October 27, 2026 | 3.280B |
| October 26, 2026 | 3.343B |
| October 23, 2026 | 3.280B |
| October 22, 2026 | 3.144B |
| October 21, 2026 | 3.282B |
| October 20, 2026 | 3.334B |
| October 19, 2026 | 3.221B |
| October 16, 2026 | 3.185B |
| October 15, 2026 | 3.167B |
| October 14, 2026 | 3.190B |
| October 13, 2026 | 3.198B |
| October 12, 2026 | 3.003B |
| Date | Value |
|---|---|
| October 09, 2026 | 3.120B |
| October 08, 2026 | 3.106B |
| October 07, 2026 | 3.119B |
| October 06, 2026 | 2.971B |
| October 05, 2026 | 3.116B |
| October 02, 2026 | 3.074B |
| October 01, 2026 | 3.257B |
| September 30, 2026 | 3.169B |
| September 29, 2026 | 3.090B |
| September 28, 2026 | 3.203B |
| September 25, 2026 | 3.252B |
| September 24, 2026 | 3.156B |
| September 23, 2026 | 3.191B |
| September 22, 2026 | 3.239B |
| September 21, 2026 | 3.217B |
| September 18, 2026 | 3.265B |
| September 17, 2026 | 3.378B |
| September 16, 2026 | 3.140B |
| September 15, 2026 | 3.291B |
| September 14, 2026 | 3.296B |
| September 11, 2026 | 3.323B |
| September 10, 2026 | 3.211B |
| September 09, 2026 | 3.453B |
| September 08, 2026 | 3.397B |
| September 04, 2026 | 3.471B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 94.93B |
| Daiichi Sankyo Co., Ltd. | 31.74B |
| Eisai Co., Ltd. | 8.931B |
| Chugai Pharmaceutical Co., Ltd. | 68.64B |
| Ono Pharmaceutical Co., Ltd. | 6.362B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 51.99M |
| Revenue (Quarterly) | 466.76M |
| Total Expenses (Quarterly) | 414.93M |
| EPS Diluted (Quarterly) | 0.1611 |
| Gross Profit Margin (Quarterly) | 55.01% |
| Profit Margin (Quarterly) | 11.14% |
| Earnings Yield | 6.02% |
| Operating Earnings Yield | 7.25% |